The USA-based company has highlited the potential of these copycat biologics to reduce costs, increase accessibility and provide patients with more options.

In 2017, it has been working on biosimilar versions of filgrastim, pegfilgrastim and adalimumab, but the company also has other products in pre-clinical development.

In January 2019, the company has been acquired by Kashiv Pharma and now operates under a new name, Kashiv BioSciences.